Patents by Inventor Jiangmei Li

Jiangmei Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES BINDING CD40 AND PD-L1 AND USES THEREOF
    Publication number: 20240084027
    Abstract: Disclosed is a multi-specific antibody targeting CD40 and PD-L1, as well as its use in the treatment of diseases such as tumors.
    Type: Application
    Filed: August 15, 2023
    Publication date: March 14, 2024
    Inventors: Jiangmei LI, Xuechen ZHOU, Wenqi HU, Feng LI
  • MOLECULES BINDING PD-L1 AND USES THEREOF
    Publication number: 20230382995
    Abstract: Disclosed is a molecule, e.g., a single-domain antibody, or a heavy chain only antibody, that specifically binds human PD-LI, and its use in treating diseases such as tumors.
    Type: Application
    Filed: May 25, 2023
    Publication date: November 30, 2023
    Inventors: Xuechen ZHOU, Guangzhong LIN, Jiangmei LI, Wenqi HU, Feng LI
  • ANTIBODIES BINDING BCMA AND CD3 AND USES THEREOF
    Publication number: 20230348630
    Abstract: Disclosed is a monoclonal antibody that specifically binds BCMA, or an antigen binding fragment thereof, and its use in treating cancers such as multiple myeloma. Also disclosed is a monoclonal antibody that specifically binds CD3, or an antigen binding fragment thereof, and its use in treating or alleviating an inflammatory disease, an autoimmune disease, or transplantation rejection. Further disclosed is an anti-BCMA/CD3 bispecific antibody, and its use in treating diseases such as cancers.
    Type: Application
    Filed: April 26, 2023
    Publication date: November 2, 2023
    Inventors: Fangjie LIU, Jiangmei LI, Wenqi HU, Feng LI
  • BISPECIFIC MOLECULES BINDING TIGIT AND VEGF AND USES THEREOF
    Publication number: 20230348629
    Abstract: Disclosed is a bispecific molecule specifically binding TIGIT and VEGF, and its use in treatment of e.g., tumors.
    Type: Application
    Filed: April 26, 2023
    Publication date: November 2, 2023
    Inventors: Jiangmei LI, Wenqi HU, Feng LI
  • SINGLE-CHAIN FRAGMENT VARIABLE COMPRISING MUTANT LIGHT CHAIN FRAMEWORK REGION
    Publication number: 20230348612
    Abstract: Disclosed is a single chain fragment variable (scFv), comprising a heavy chain variable region, a linker and a ? light chain variable region, wherein the ? light chain variable region is engineered to comprise leucin (L), threonine (T) and alanine (A) at Position 104 to 106 according to the Kabat numbering scheme.
    Type: Application
    Filed: April 26, 2023
    Publication date: November 2, 2023
    Inventors: Guangzhong LIN, Jiangmei LI, Wenqi HU, Feng LI
  • Antibodies binding PD-L1 and uses thereof
    Patent number: 11718674
    Abstract: An isolated monoclonal antibody, or an antigen-binding portion thereof, that specifically binds human PD0-L1. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immuneconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the antibody or antigen-binding portion thereof.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: August 8, 2023
    Assignee: BEIJING MABWORKS BIOTECH CO., LTD.
    Inventors: Jiangmei Li, Wenqi Hu, Feng Li
  • ANTIBODIES BINDING TIGIT AND USES THEREOF
    Publication number: 20220396617
    Abstract: An isolated monoclonal antibody, or an antigen-binding portion thereof, that specifically binds human TIGIT. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the antibody or antigen-binding portion thereof.
    Type: Application
    Filed: August 30, 2021
    Publication date: December 15, 2022
    Inventors: Jiangmei LI, Wenqi HU, Feng LI
  • ANTIBODIES BINDING PD-L1 AND USES THEREOF
    Publication number: 20220298244
    Abstract: An isolated monoclonal antibody, or an antigen-binding portion thereof, that specifically binds human PD-L1. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immuneconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the antibody or antigen-binding portion thereof.
    Type: Application
    Filed: August 30, 2021
    Publication date: September 22, 2022
    Inventors: Jiangmei LI, Wenqi HU, Feng LI
  • ANTIBODIES BINDING HUMAN AND MONKEY CD3 AND USES THEREOF
    Publication number: 20220195043
    Abstract: Disclosed is a monoclonal antibody that binds human and monkey CD3, or an antigen-binding portion thereof, as well as the use of the antibody or antigen-binding portion thereof in treatment of inflammatory diseases and in preparation of bispecific antibodies. A bispecific antibody against e.g., CD3 and CD20 comprising the antibody or antigen-binding portion thereof of the disclosure, and the use of the bispecific antibody in treatment of diseases such as cancers are also provided.
    Type: Application
    Filed: August 30, 2021
    Publication date: June 23, 2022
    Inventors: Jiangmei LI, Fangjie LIU, Chunyang JIN, Yu LIU, Sijia HUANG, Feng LI
  • Anti-OX40 antibodies and uses thereof
    Patent number: 11091558
    Abstract: An isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human OX40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-OX40 antibody of the invention.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: August 17, 2021
    Assignee: BEIJING MABWORKS BIOTECH CO. LTD.
    Inventors: Wenqi Hu, Jiangmei Li, Lun Jiang, Feng Li
  • Antibodies binding LAG3 and methods of treatment using them
    Patent number: 10946092
    Abstract: An isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human LAG3. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immuneconjugate, a bispecific molecule, a chimeric antigen receptor, and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof thereof, as well as a treatment method using the same.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: March 16, 2021
    Assignees: BEIJING MABWORKS BIOTECH CO., LTD., BEIJING MABRIDGE BIOPHARMACEUTICAL CO., LTD.
    Inventors: Wenqi Hu, Jiangmei Li, Feng Li
  • ANTI-OX40 ANTIBODIES AND USES THEREOF
    Publication number: 20200231692
    Abstract: An isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human OX40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-OX40 antibody of the invention.
    Type: Application
    Filed: October 14, 2019
    Publication date: July 23, 2020
    Inventors: Wenqi HU, Jiangmei Li, Lun Jiang, Feng Li
  • Antibodies targeting CD40 and uses thereof
    Patent number: 10662249
    Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: May 26, 2020
    Assignees: BEIJING MABWORKS BIOTECH CO., LTD., BEIJING MABRIDGE BIOPHARMACEUTICAL CO., LTD.
    Inventors: Wenqi Hu, Jiangmei Li, Feng Li
  • CD40 specific antibodies and uses thereof
    Patent number: 10654937
    Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: May 19, 2020
    Assignees: BEIJING MABWORKS BIOTECH CO., LTD., BEIJING MABRIDGE BIOPHARMACEUTICAL CO., LTD.
    Inventors: Wenqi Hu, Jiangmei Li, Feng Li
  • Antibodies specific to CD40 and uses thereof
    Patent number: 10654939
    Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: May 19, 2020
    Assignees: BEIJING MABWORKS BIOTECH CO., LTD., BEIJING MABRIDGE BIOPHARMACEUTICAL CO., LTD.
    Inventors: Wenqi Hu, Jiangmei Li, Feng Li
  • CD40 binding antibodies and uses thereof
    Patent number: 10654938
    Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: May 19, 2020
    Assignees: BEIJING MABWORKS BIOTECH CO., LTD., BEIJING MABRIDGE BIOPHARMACEUTICAL CO., LTD.
    Inventors: Wenqi Hu, Jiangmei Li, Feng Li
  • Anti-CD40 antibodies and uses thereof
    Patent number: 10647776
    Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: May 12, 2020
    Assignees: BEIJING MABWORKS BIOTECH CO., LTD., BEIJING MABRIDGE BIOPHARMACEUTICAL CO., LTD.
    Inventors: Wenqi Hu, Jiangmei Li, Feng Li
  • Antibodies binding VISTA and uses thereof
    Patent number: 10577424
    Abstract: An isolated monoclonal antibody or the antigen binding portion thereof that specifically binds human VISTA. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody or the antigen binding portion thereof are also provided. The present disclosure further provides a bispecific molecule, and a pharmaceutical composition comprising the antibody or the binding moieties thereof, as well as a treatment method using an anti-VISTA antibody or the antigen binding portion thereof of the present disclosure.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: March 3, 2020
    Assignee: Beijing Mabworks Biotech Co., Ltd.
    Inventors: Wenqi Hu, Jiangmei Li, Feng Li
  • Antibodies binding CD40 and uses thereof
    Patent number: 10570210
    Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: February 25, 2020
    Assignee: Beijing Mabworks Biotech Co.Ltd
    Inventors: Wenqi Hu, Jiangmei Li, Feng Li
  • Antibodies binding OX40 and uses thereof
    Patent number: 10442866
    Abstract: An isolated monoclonal antibody that specifically binds human OX40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-OX40 antibody of the invention.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: October 15, 2019
    Assignee: Beijing Mabworks Biotech Co. Ltd
    Inventors: Wenqi Hu, Jiangmei Li, Lun Jiang, Feng Li